Economy · India
Cipla partners with China's Qilu Pharma for cancer drug biosimilar
Indian pharmaceutical company Cipla has entered into a partnership with China's Qilu Pharmaceutical to develop and commercialize a biosimilar for the cancer drug Pembrolizumab. The deal grants Cipla the rights to market the biosimilar in the United States. This collaboration aims to strengthen Cipla's oncology portfolio and capitalize on the long-term potential of biosimilars. The partnership was announced following a period where Cipla's stock experienced a decline, with analysts noting the competitive landscape for such drugs.
How outlets across the spectrum covered it
L 1 C 2 R 0
- Left (1): The Hindu
- Centre (2): The Economic Times, The Hindu BusinessLine